Kidney Disease
DAPA-CKD trial stopped early after ‘overwhelming benefit’ observed with dapagliflozin
The phase 3 DAPA-CKD trial assessing the benefit of the SGLT2 inhibitor dapagliflozin in adults with chronic kidney disease will be stopped early after investigators reported an “overwhelming benefit” for reduction in worsening renal function or renal death compared with placebo, according to a press release from AstraZeneca.
Daily text messages could help improve diet, lifestyle for patients with CKD
Cigna, Cricket Health expand partnership to improve CKD care
AKF launches COVID-19 emergency fund for low-income patients with kidney disease
CVD, cancer, depression influence kidney disease risk in diabetes
A long-term follow-up of Australian adults with diabetes suggests the age-adjusted incidence rate of chronic kidney disease was six new cases per 100 person-years during a span of 11 years, with comorbidities such as cardiovascular disease, cancer, obesity and depression all driving the higher risk for renal function decline, according to findings published in Diabetes Care.
American Kidney Fund outlines efforts for Kidney Month
Oral anticoagulation may be harmful in AF, end-stage renal disease
Excluding patient race when estimating GFR may lead to error
Cricket Health’s virtual care program may improve understanding of CKD
CVS partners with Satellite-Healthcare to advance kidney care efforts
CVS Kidney Care has partnered with Satellite Healthcare to bolster its efforts in improving care for patients with kidney disease, according to a press release from CVS Health. Ascend Clinical, a company that provides clinical laboratory testing services for dialysis clinics, will also take part in these efforts.